Downregulation of AQP1, -2, and -3 after
ureteral obstruction is associated with a long-term
urine-concentrating defect
Chunling
Li1,2,
Weidong
Wang3,
Tae-Hwan
Kwon3,
Levent
Isikay1,
Jian Guo
Wen1,
David
Marples4,
Jens Christian
Djurhuus1,
Anette
Stockwell1,
Mark A.
Knepper5,
Søren
Nielsen3, and
Jørgen
Frøkiær1,2
1 Institute of Experimental Clinical Research, University of
Aarhus, DK-8200 Aarhus N; 2 Department of Clinical Physiology,
Aarhus University Hospital-Skejby, DK-8200 Aarhus N;
3 Department of Cell Biology, Institute of Anatomy, University
of Aarhus, DK-8000 Aarhus C, Denmark; 4 School of
Biomedical Sciences, University of Leeds, Leeds LS2 9NQ, United
Kingdom; and 5 Laboratory of Kidney and Electrolyte
Metabolism, National Heart, Lung and Blood Institute, National
Institutes of Health, Bethesda, Maryland 20892
 |
ABSTRACT |
Previously, we demonstrated that 24 h of bilateral ureteral
obstruction (BUO) and short-term release of BUO was associated with a
decrease in the expression of aquaporin-2 (AQP2), polyuria, and a
reduced urinary concentrating capacity (10). The purposes of the present study were to examine whether BUO and the long-term release of BUO (BUO-R) for 3, 14, and 30 days were associated with
changes in the expression of renal AQP1, AQP2, and AQP3 and whether
such changes were associated with parallel changes in urinary output
and urinary concentrating capacity. Rats (n = 4-7 in each group) were kept in metabolic cages for measurements of urinary
output. Kidneys were removed to determine the expression levels of
AQP1, AQP2, and AQP3 by semiquantitative immunoblotting. AQP2 was
downregulated after 24 h of BUO (42 ± 3%). Downregulation of AQP2 persisted 3 (43 ± 14%; P < 0.01) and 15 days after BUO-R (48 ± 11%; P < 0.01) but was
normalized 30 days after BUO-R. AQP3 showed a similar pattern.
Moreover, AQP1 was downregulated in response to BUO (65 ± 7%)
and remained downregulated 3 days after BUO-R (41 ± 5%), 14 days
after BUO-R (57 ± 8%), and 30 days after BUO-R (59 ± 5%).
BUO-R resulted in a significant polyuria that gradually decreased,
although it remained significant at day 30. Urinary
concentrating capacity remained significantly impaired when determined
3, 14, and 30 days after BUO-R in response to a 24-h period of thirst
(1,712 ± 270 vs. 2,880 ± 91 mosmol/kgH2O at
day 30, P < 0.05). In conclusion, the
expression of AQP1, AQP2, and AQP3 were long-term downregulated after
BUO-R, suggesting that dysregulation of aquaporins located at the
proximal tubule, thin descending limb of the loop of Henle, and the
collecting duct may contribute to the long-term polyuria and impairment
of urinary concentrating capacity associated with obstructive nephropathy.
collecting duct; nephrogenic diabetes insipidus; obstructive
nephropathy; polyuria; proximal tubule; aquaporin-1; aquaporin-2; aquaporin-3
 |
INTRODUCTION |
BILATERAL URINARY TRACT
OBSTRUCTION (BUO) is a serious condition both in children and
adults and may be associated with long-term impairment in the ability
to concentrate urine (4). The pathophysiology behind the
loss of urinary concentrating ability is complex and involves both the
juxtamedullary, proximal and distal tubules, the loops of Henle, and
the collecting ducts (4). Detailed clearance studies
showing impaired water reabsorption at the collecting duct level during
BUO (43), together with the clinical observations that
patients with obstructive nephropathy have massive
vasopressin-insensitive polyuria after relief from obstruction,
demonstrate that BUO is associated with nephrogenic diabetes insipidus
(NDI). Consistent with this, we previously demonstrated that BUO for
24 h in rats is associated with a significant downregulation of
the vasopressin-regulated collecting duct water channel aquaporin-2
(AQP2), and this downregulation persists 24 and 48 h after release
of obstruction concurrent with a marked postobstructive polyuria
(10). Seven days after release of obstruction, AQP2 levels
were only partially reversed to normal levels, and consistent with this
urinary concentrating capacity remained significantly reduced 7 days
after release of BUO, as determined in response to 18 h of
thirsting (10). To examine whether this downregulation was
caused by local effects or systemic changes, rats with unilateral
ureteral obstruction (UUO) were examined (8). Similar to
the downregulation found in bilateral obstruction, rats with UUO for
24 h also had AQP2 downregulation to the same level as in BUO,
suggesting that local/intrarenal factors may be important for
downregulation (8). Importantly, separate experiments
where AQP2 expression and solute-free water clearance were examined
immediately after the release of a 24-h UUO revealed that changes in
AQP2 expression are reciprocal to the changes in solute-free free water
clearance, which indicates a functional association between these two
parameters (8). Thus this finding supports the
view that the collecting duct is critically involved in the impaired
urinary concentrating capacity in urinary tract obstruction.
Recently, a critical role of AQP1 in the transcellular water
reabsorption of the proximal nephron and in the urinary concentration was demonstrated in transgenic knockout mice lacking AQP1
(25). The AQP1-deficient mice were unable to concentrate
urine in response to thirsting and became severely dehydrated, strongly
suggesting that AQP1 is required for the formation of a concentrated
urine. Furthermore, defects in fluid reabsorption were demonstrated in these transgenic AQP1 knockout mice both at the proximal tubule and the
descending limb of Henle (38). In the proximal tubule, transepithelial osmotic water permeability was reduced by 80% (38), and in the descending thin limb it was reduced by
90% (2). Water transport across the basolateral plasma
membrane of collecting duct principal cells is thought to be mediated
by AQP3 and AQP4. Consistent with this view, recent studies by Ma et
al. (25) showed a >10-fold greater fluid consumption and a much lower urine osmolality in AQP3 null mice compared with wild-type
mice. In response to water deprivation and vasopressin administration,
renal concentration capacity in AQP3 null mice only returned to about
30% of that in wild-type mice (24). Morever, inner
medullary collecting ducts from AQP4-deficient mice have a fourfold
reduction in vasopressin-stimulated water permeability (3). This finding suggests that AQP2 in the apical plasma
membrane of principal cells, AQP3 and AQP4 located in the basolateral
plasma membrane of principal cells in collecting tubules
(16), and AQP1 in proximal nephron cells are all important
for the formation of concentrated urine. In support of this
view, we recently demonstrated that AQP1, -2, and -3 abundance are
severely reduced in response to experimental acute (12)
and chronic renal failure (22, 23), which both are
associated with significant polyuria/impaired urinary-concentration
capacity, suggesting that AQP1, -2, and -3 may play critical roles in
the urinary concentration mechanisms in complex renal disorders.
The purposes of the present study are therefore to examine
1) whether there are long-term changes in the expression
levels of aquaporins located in both the proximal tubule and descending limb (AQP1) and the collecting duct (AQP2 and AQP3) after release of
BUO; and 2) whether such changes are associated with
long-term changes in the urinary concentrating capacity. The results of the present study show that AQP1, -2, and -3 are long-term
downregulated and that urinary concentrating capacity is reduced up to
30 days after the release of 24-h bilateral ureteral obstruction,
indicating that both the proximal nephron and collecting duct play
critical roles in the concentrating defect seen in obstructive nephropathy.
 |
METHODS |
Experimental animals.
Studies were performed in male Münich Wistar rats initially
weighing 250 g (Møllegard Breeding Center, Eiby, Denmark). The rats were maintained on a standard rodent diet (Altromin, Lage, Germany) with free access to water. During the entire experiment, rats
were kept in individual metabolic cages with a 12:12-h artificial light-dark cycle, a temperature of 21 ± 2°C, and a humidity of 55 ± 2%. Rats were allowed to acclimatize to the cages for 5 to 7 days before surgery.
The rats were anesthetized with halothane (Halocarbon Laboratories),
and during surgery the rats were placed on a heated table to maintain
rectal temperature at 37-38°C. Through a midline abdominal incision, both ureters were exposed, and a 5-mm-long piece of bisected
polyethylene tubing (PE-50) was placed around the midportion of each
ureter. The ureter was then occluded by tightening the tubing with a
5-0 silk ligature. Twenty-four hours later, the obstructed ureters
were decompressed by removal of the ligature and the PE tubing. By
using this technique, the ureters could be completely occluded for
24 h without evidence of subsequent functional impairment of
ureteral function.
Rats were allocated to the protocols indicated below. Age- and
time-matched sham-operated controls were prepared, and were observed in
parallel with each BUO group in the following protocols (Fig.
1):

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
Diagram of the study design. Protocol 1:
bilateral ureteral obstruction (BUO) was created. Sham-operated control
rats matching BUO rats are shown. Protocol 2: BUO was
created and released after 24 h. Rats are then monitored for the
following 3 days, sham-operated control rats matching BUO rats.
Protocol 3: BUO was created and released after 24 h.
Rats were then monitored for the following 14 days, sham-operated
control rats matching BUO rats. Protocol 4: BUO was created
and released after 24 h. Rats were then monitored for the
following 30 days, sham-operated control rats matching BUO rats.
Protocol 5: BUO was created and released after 24 h.
Rats were then monitored for the following 3 days, and after 3 days
release rats were thirsted for 24 h, sham-operated control rats
matching BUO rats. Protocol 6: BUO was created and released
after 24 h. Rats were then monitored for the following 30 days,
and after 11 and 29 days release rats were thirsted for 24 h,
sham-operated control rats matching BUO rats. All rats were kept in
metabolic cages during the entire study. Urine osmolality, creatinine,
sodium, and potassium were measured. Plasma was collected at the time
of death for measurement of osmolality and concentration of sodium,
potassium, and creatinine.
|
|
Protocol 1. BUO was induced (n = 6) for
24 h or rats were sham operated (n = 6). The two
kidneys were removed and separately prepared for semiquantitative immunoblotting.
Protocol 2. BUO was induced for 24 h or rats were sham
operated (n = 6), followed by release in which animals
were observed during the next 3 days (n = 5). The two
kidneys were removed and separately prepared for semiquantitative immunoblotting.
Protocol 3. BUO was induced for 24 h or rats were sham
operated (n = 6), followed by release in which animals
were observed during the next 14 days (n = 6). The two
kidneys were removed and separately prepared for semiquantitative immunoblotting.
Protocol 4. BUO was induced for 24 h or rats were sham
operated (n = 6), followed by release in which animals
were observed during the next 30 days (n = 6). Kidneys
were removed and separately prepared for semiquantitative immunoblotting.
Protocol 5. BUO was induced for 24 h or rats were sham
operated (n = 4), followed by release in which animals
were observed during the next 3 days (n = 4).
Urinary-concentrating capacity was examined in response to a 24-h
period of thirst after release of BUO for 2 days.
Protocol 6. BUO was induced for 24 h or rats were sham
operated (n = 5), followed by release in which animals
were observed for 30 days (n = 7).
Urinary-concentrating capacity was examined in response to a 24-h
period of thirst at day 11 and 29 after release.
Clearance studies.
Urine was collected during 24-h periods throughout the study. Clearance
studies were performed during the last 24 h in each protocol.
During anaesthesia, at the end of each protocol, 2-3 ml of blood
were collected into a heparinized tube for the determination of plasma
electrolytes and osmolality before the rat was killed. The plasma and
urinary concentrations of creatinine and urea and the plasma
concentrations of sodium and potassium were determined (Kodak Ektachem
700XRC). The concentrations of urinary sodium and potassium were
determined by standard flame photometry (Eppendorf FCM6341). The
osmolality of urine and plasma was measured with a vapor pressure
osmometer (Osmomat 030, Gonotec).
Membrane fractionation for immunoblotting.
For removal of kidneys, rats were anesthetized with halothane. One
kidney was split into cortex, outer medulla, and inner medulla (IM) and
frozen in liquid nitrogen. The other whole kidney (WK) was frozen in
liquid nitrogen. Tissue (IM or WK) was minced finely and homogenized in
1 ml (IM) or 9 ml (WK) of dissecting buffer (0.3 M sucrose, 25 mM
imidazole, 1 mM EDTA, pH 7.2, containing protease inhibitors: 8.5 µM leupeptin and 1 mM phenylmethylsulfonyl fluoride) with
five strokes of a motor-driven Potter-Elvehjem homogenizer at 1,250 rpm. This homogenate was centrifuged in a Beckman L8M centrifuge at
4,000 g for 15 min at 4°C. The supernatants were
centrifuged at 200,000 g for 1 h. The resultant pellet
was resuspended in ~100 µl of dissecting buffer and assayed for
protein concentration by using the method of Lowry. Gel samples (in
Laemmli sample buffer containing 2% SDS) were made from this membrane preparation.
Electrophoresis and immunoblotting.
Samples of membrane fractions from IM or whole kidney were run on 12%
polyacrylamide minigels (Biorad Mini Protean II). For each gel, an
identical gel was run in parallel and subjected to Coomassie staining
(42). The Coomassie-stained gel was used to ascertain
identical loading or to allow for potential correction for minor
differences in loading after scanning and densitometry of major bands
(see below). The other gel was subjected to blotting. After transfer by
electroelution to nitrocellulose membranes, blots were blocked with 5%
milk in 80 mM Na2HPO4, 20 mM
NaH2PO4, 100 mM NaCl, and 0.1% Tween 20, pH
7.5 (PBS-T) for 1 h and incubated with antibody raised against the
COOH-terminal 22 amino acids of AQP2 (either serum, diluted 1:1,000, or
affinity purified with the immunizing peptide, diluted to 40 ng
IgG/µl in PBS-T plus 1% BSA) (29-31),
AQP1-immune serum (diluted 1:2,000) (33), or with
affinity-purified anti-AQP3 (0.5 µg/ml) (7) overnight. After being washed as above, the blots were incubated with horseradish peroxidase-conjugated secondary antibody (P448, Dako, Glostrup, Denmark, diluted 1:3,000). After a final wash as above, antibody binding was visualized using the enhanced chemiluminescence (ECL) system (Amersham International). Controls were made with the exchange of primary antibody to antibody preabsorbed with immunizing peptide (100 ng/40 ng IgG) or with preimmune serum (diluted 1:1,000). All
controls were without labeling.
Semiquantitation of AQP1, AQP2, and
AQP3.
ECL films were scanned using a Hewlett-Packard Scanjet scanner and
Adobe Photoshop software. For AQP1 and AQP2 both the 29-kDa and the 35- to 50-kDa bands [corresponding to nonglycosylated and glycosylated
AQP1 and AQP2 (26, 42)] were scanned. For AQP3, the
27-kDa and the 33- to 40-kDa bands (corresponding to nonglycosylated
and glycosylated AQP3) were scanned, as described previously (7,
42). The labeling density was quantitated by using specially
written software (available on request). Bands from gels made with
serial dilutions of protein from IM, processed as above, were found to
be linear over a wide range (26). For quantitation of AQP2
expression, ECL exposures were chosen that gave bands in the control
samples that were close to the top of the linear range. To correct for
potential minor differences in loading between lanes, Coomassie-stained
gels, which were run in parallel to the immunoblotted gels, were
subjected to band density scanning.
Statistics.
For densitometry of immunoblots, samples from obstructed kidneys were
run on each gel with corresponding sham kidneys. AQPs labeled in the
samples from the experimental animals were calculated as a fraction of
the mean sham control value for that gel. Parallel Coomassie-stained
gels were subjected to densitometry and used for correction of
potential minor differences in loading. Values are presented in the
text as means ± SE. Comparisons among groups were made by
unpaired t-test. P values < 0.05 were
considered significant.
 |
RESULTS |
Release of BUO is followed by polyuria and long-term
impairment in urinary concentrating capacity.
Water intake, urine output, and urine osmolality were determined in
rats followed for 30 days after release of a 24-h period of BUO. As
previously shown, release of BUO resulted in a highly significant
increase in urine output and a parallel reduction in urine osmolality
(Table 1). Twenty-four hours after
release of BUO, urine output was 127 ± 7 µl · min
1 · kg
1 compared
with 34 ± 4 µl · min
1 · kg
1 before
obstruction. Consistent with this, the urine osmolalities were reduced
from 1,845 ± 145 to 505 ± 40 mosmol/kgH2O.
During the following 14 days, urine output remained significantly
elevated compared with sham-operated controls. The marked increase in
urine output after release of BUO was reproduced in separate
experiments (protocols 3 and 5 ) where rats were
followed for 3 and 14 days after release of BUO (Table 1). We have
previously shown that urine-concentrating capacity was impaired in rats
7 days after release of obstruction. Consistent with this, we found an
impaired urinary concentrating capacity in response to 24 h of
thirsting at day 3 after release of BUO (see protocol
5, Fig. 3). Next, we tested whether rats have long-term impairment
in urinary concentrating capacity by subjecting the animals to a 24-h
period of thirst at day 11 and again at day 29 after the release of obstruction. As shown in Figs.
2 and
3, urine-concentrating capacity
remained significantly impaired compared with sham-operated control
animals. At 3, 12, and 30 days after BUO-R, animals were unable to
increase urine osmolalities and reduce urine output to the same level
as the sham-operated controls, consistent with a long-term impairment in urine-concentrating capacity after the release of 24 h of BUO.
View this table:
[in this window]
[in a new window]
|
Table 1.
Changes in free water clearance, urine volume, and osmolality in
nonthirsted rats subjected to BUO and release of BUO or sham operation
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Urine output and urine osmolality in BUO are compared
with matched sham-operated control rats observed for 30 days after
release of obstruction, and at 12 and 30 days were subjected to a 24-h
period of thirst. Release of BUO resulted in a marked increase in urine
production that slowly declined in the postrelease period. However,
urine production was still elevated in the BUO group 30 days after
release, and urine osmolality remained persistantly decreased during
the entire period in the BUO group compared with the sham-operated
controls.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Urine output and urine osmolality were examined in
separate experiments (protocols 5 and 6) in BUO
rats (solid bars) and compared with matched sham-operated control rats
(open bars). All animals were subjected to a 24-h thirst before death
to examine urinary concentrating capacity. These experiments reveal a
persistant reduction in urinary concentrating capacity during the first
30 days after release of BUO. Three days after release of BUO urine
osmolality was significantly reduced (1,051 ± 115 vs. 2,242 ± 156 mosmol/kgH2O, n = 4, *P < 0.01). Twelve and thirty days after release of
BUO another set of rats were subjected to 24 h of thirsting, which
demonstrates that urine osmolality remains significantly reduced
(1,675 ± 274, n = 7, vs. 3,186 ± 124 mosmol/kgH2O, P < 0.01 after 12 days, and
1,712 ± 270, n = 5, vs. 2,879 ± 91 mosmol/kgH2O, *P < 0.01 after 30 days).
|
|
BUO and release of BUO is associated
with long-term downregulation of both AQP2 and
AQP3.
As previously shown, the affinity-purified anti-AQP2 antibody
exclusively recognizes the 29-kDa and the 35- to 50-kDa bands (Fig.
4A), corresponding to
nonglycosylated and glycosylated forms of AQP2 (36).
Consistent with previous data (26) (Fig. 4, A
and E), immunoblotting using whole kidney membrane fractions of obstructed kidneys and sham-operated control animals revealed that
AQP2 expression was significantly downregulated 3 days after release of
BUO (43 ± 14 vs. 100 ± 7%, P < 0.01; Fig.
4, B and E). Fourteen days after release of
obstruction, immunoblotting showed a persistent reduction in AQP2
levels (Fig. 4C). Densitometry demonstrated that AQP2 levels
were 48 ± 11% of sham-operated control levels (Fig.
4E). This is consistent with the persistent polyuria and
impaired urine-concentrating capacity observed 14 days after release of
BUO (Fig. 2).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Semiquantitative immunoblotting of membrane fractions of inner
medulla (IM). A-D: immunoblots were reacted with
anti-aquaporin-2 (anti-AQP2) and reveal 28-kDa and the 35- to 45-kDa
AQP2 bands, representing nonglycosylated and glycosylated forms
of AQP2 after 24 h of BUO (A); 3 days after
release of BUO (B); 14 days after release of BUO
(C); and 30 days after release of BUO (D).
E: densitometric analysis of all samples from BUO and
sham-operated rats (corrected according to loading) reveal a persisted
decrease in AQP2 expression in rats with BUO and 3 and 14 days after
release of BUO (24-hBUO: 42 ± 7 vs. 100 ± 6%; BUO-3daysR:
43 ± 14 vs. 100 ± 7%; BUO-14daysR: 48 ± 11 vs.
100 ± 5%, *P < 0.05), but 30 days after release
of BUO, AQP2 levels did not differ significantly from sham operated.
|
|
Although urine output remained elevated in the BUO animals compared
with sham-operated animals throughout the experiment, there was a
steady decrease from day 10 in all groups (Fig. 2 and Table
1). Immunoblotting and densitometry revealed that AQP2 levels were
normalized 30 days after release of BUO (79 ± 11 vs. 100 ± 28%; Fig. 4, D and E).
Another water channel located in collecting tubule, AQP3, also was
examined. A dramatic reduction in the expression of IM AQP3 levels was
shown in rats with 24-h BUO, from 100 ± 10 to 8 ± 2% (Fig.
5, A and D,
P < 0.05). Three days after the release of BUO, AQP3
levels were significantly decreased (50 ± 8% of sham level, Fig.
5, B and D, P < 0.05). This
decrease in AQP3 expression was also seen 14 days after BUO-R ( 36 ± 12% of sham level, Fig. 5, C and D,
P < 0.05), whereas AQP3 expression was normalized 30 days after release of BUO (92 ± 22 vs. 100 ± 15%; Fig. 5,
D and E).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Semiquantitative immunoblotting of membrane fractions of IM.
A-D: immunoblots were reacted with anti-AQP3 serum and
reveal 27-kDa and 33- to 40-kDa AQP3 bands, representing
nonglycosylated and glycosylated forms of AQP3 after 24 h of BUO
(A); 3 days after release of BUO (B); 14 days
after release of BUO (C); and 30 days after release of BUO
(D). E: densitometric analysis of all samples
from BUO and sham-operated rats (corrected according to loading) reveal
a marked decrease in AQP3 expression (8 ± 2% in BUO rats and
100 ± 10% in sham-operated rats, *P < 0.05).
AQP3 expression levels remain downregulated 3 and 14 days after release
( BUO-3daysR: 50 ± 8 vs. 100 ± 7%,*P < 0.05; BUO-14daysR: 36 ± 12 vs. 100 ± 16%,*P < 0.05). AQP3 expression levels did not differ
between BUO-R and sham 30 days after release of BUO (92 ± 22 vs.
100 ± 15%).
|
|
BUO and release of BUO is associated
with persistant downregulation of AQP1.
The expression of AQP1 was also examined to test whether this water
channel in the proximal tubule and thin descending limb of the loop of
Henle contributes to the long-term reduced urinary concentrating
capacity seen after the release of BUO. As shown in Fig.
6, densitometric comparison of WK AQP1
expression levels between BUO and sham-operated animals revealed a
persistant downregulation of AQP1 up to 30 days after release of
obstruction. AQP1 expression decreased markedly in response to BUO from
100 ± 7 to 65 ± 7% (Fig. 6, A and E,
*P < 0.05). Three days after BUO-R, there was a marked
decrease in total kidney AQP1 expression to 41 ± 5% in BUO rat,
of levels in sham-operated rats (100 ± 6%; Fig. 6, B and E, P < 0.05). AQP1 expression levels
remained downregulated 14 and 30 days after the release of BUO
(BUO-14daysR: 36 ± 10 vs. 100 ± 9%; BUO-30daysR: 59 ± 5 vs. 100 ± 11%, Fig. 6 C, D, and
E, P < 0.05).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Semiquantitative immunoblotting of membrane fractions of whole
kidney from BUO rats and sham (A), and membrane fractions of
outer medulla and cortex from rats 3, 14, and 30 days after release of
BUO and sham-operated rats (B-D). Immunoblots were reacted
with anti-AQP1 serum and reveal 29-kDa and 35- to 50-kDa AQP1 bands,
representing nonglycosylated and glycosylated forms of AQP1.
E: densitometric analysis of all samples from BUO and
sham-operated rats (corrected according to loading) reveal a marked
decrease in AQP1 expression in response to 24 h of BUO (65 ± 7 in BUO rats and 100 ± 7% in sham-operated rats,
*P < 0.05). AQP1 expression remained reduced 3, 14, and 30 days after release of BUO (BUO-3daysR: 41 ± 5 vs. 100 ± 6%, P < 0.05; BUO-14daysR: 36 ± 10 vs.
100 ± 9%, P < 0.05; BUO-30daysR: 59 ± 5 vs. 100 ± 11%, *P < 0.05).
|
|
Because changes in AQP1 expression in the descending limb of Henle's
loop may directly affect urinary concentrating capacity, AQP1
expression levels were examined in the IM. AQP1 was significantly downregulated 14 days after release of BUO (Fig.
7, A and B). In
contrast to the expression levels demonstrated in whole kidney samples,
no significant changes were detectable at earlier and later stages
after release of obstruction.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 7.
Semiquantitative immunoblotting of membrane fractions of
IM from rats 14 days after release of BUO and sham-operated rats.
A: the immunoblot was reacted with anti-AQP1 serum and
reveals 29-kDa and 35- to 50-kDa AQP1 bands, representing
nonglycosylated and glycosylated forms of AQP1. B:
densitometric analysis of all samples from BUO-14daysR and
sham-operated rats reveal a marked decrease in AQP1 expression (58 ± 6% in BUO rats and 100 ± 16% in sham-operated rats,
*P < 0.05).
|
|
 |
DISCUSSION |
Previously, we demonstrated that 24 h of BUO is associated
with a significant reduction in the expression of AQP2. After release of BUO, the expression of AQP2 remains downregulated, coinciding with
the onset of polyuria. This study confirmed that release of BUO is
associated with a dramatic polyuria and impaired urinary concentrating
capacity that may last up to 30 days. In parallel, the expression of
AQP1, -2, and -3 was significantly downregulated. The results of the
present study support the view that AQP1, -2, and -3 play important
roles for an intact urinary concentrating capacity and suggest that
decreased levels of aquaporins in both the proximal nephron and
collecting duct may play a significant role in the impairment of
urinary concentrating capacity after release of urinary tract obstruction.
Persistent reduction in urinary concentrating capacity after
release of obstruction parallels downregulation of AQP2.
The urinary concentrating process is dependent on two fundamental
processes: 1) the hypertonic medullary interstitium, which is generated by active NaCl reabsorption as a consequence of
countercurrent multiplication in water-impermeable nephron segments and
2) the high water permeability (constitutive or vasopressin
regulated) in other renal tubular segments for osmotic equilibration,
which chiefly depends on aquaporins. Thus defects in any of these
mechanisms would be predicted to be associated with urinary
concentrating defects. Release of BUO is associated with an immediate
significant polyuria (5, 14, 39, 43), which can be
attributed to several functional defects in the kidney compromising
either generation of a hypertonic medullary interstitium or
vasopressin-regulated water transport across the collecting duct
epithelium. These defects include 1) a reduction in
glomerular filtration rate; 2) an increase in medullary
blood flow; 3) a sustained increase in intraluminal and
parenchymal pressure, changing transport abilities in the nephrons and
collecting ducts; 4) a reduced fractional reabsorption of
fluid from the nephron; and 5) a collecting duct dysfunction that caused alterations in sodium and water transport in this segment
(4). Indeed, it has been well established that
postobstructive polyuria is resistant to vasopressin treatment
(43). In the present study, we demonstrated that release
of BUO is associated with a persistent impairment of urinary
concentrating capacity lasting up to 30 days after release of
obstruction. In parallel, AQP2 expression was downregulated after
24 h of BUO, and, at 3 and 14 days after release of BUO it was
consistent with the development of polyuria, decreased urine
osmolality, and increased free water clearance. These results extend
our previous findings, where AQP2 remained downregulated up to 7 days
after the release of BUO. Thus downregulation of the
vasopressin-regulated collecting duct AQP2 may play an important role
in polyuria and long-term impairment of urinary concentration after
release of BUO.
The mechanisms responsible for the long-term AQP2 downregulation remain
incompletely understood. The water permeability of the collecting duct
can change acutely in response to vasopressin via V2
receptor-mediated stimulation of cAMP, leading to phosphorylation and
translocation of AQP2 to the apical plasma membrane (19, 32). In addition to this acute regulation of collecting duct water permeability, it is now well established that there is a long-term modulation of the water permeability dependent on the total
amount of AQP2 present in the principal cells (18, 21, 28). Initially, this was documented in rats with lithium-induced NDI (26, 28) and subsequently in NDI caused by hypokalemia (27) and hypercalcemia (6, 34). In addition,
AQP2 downregulation has been described in other situations not
generally thought of as acquired forms of NDI. Among these are a
protein-deficient diet and aging, which have been shown to cause
changes in water reabsorption (35, 41). Thus AQP2
downregulation of AQP2 is a common feature in multiple forms of NDI and
non-NDI conditions characterized by urinary concentrating defects.
Release of BUO is associated with polyuria, despite high levels of
circulating vasopressin. Thus it is possible that BUO causes a change
in the number of functional V2 receptors and/or a reduction
in the abundance of adenylate cyclase and other intracellular enzymes,
playing a key role as an intact second message of the vasopressin
signal. However, it should be emphasized that, at this stage, very
little is known, and additional studies must be undertaken to address these questions. Furthermore, we have previously shown that AQP2 expression levels are reduced in both the obstructed kidney and the
nonobstructed kidney in a rat model with UUO, suggesting that local
factors are involved in the dysregulation of AQP2 during obstruction.
Such factors could be an increased luminal pressure and/or altered
prostaglandin or nitric oxide (NO) production (17). NO is
a chemical form of endothelium-derived relaxing factor that has
important roles in renal hemodynamics and renal sodium and water
metabolism (12, 40). Recently, it was shown directly that
NO inhibits vasopressin-stimulated osmotic water permeability in
isolated and perfused cortical collecting duct (11).
Whether there are long-term alterations in the production of
prostaglandins or NO in the kidney after release of 24-h BUO remains to
be established. The present findings show that AQP2 downregulation is a
prominent finding during and after release of obstruction, and the
results suggest that downregulation of AQP2 may at least partially be responsible for the lack in urinary concentrating capacity observed in
patients with congenital or acquired disorders of the urinary tract,
causing long-term bilateral impairment of renal function (i.e.,
ureteral valves, high grade reflux, or neurogenic bladder).
BUO and release of BUO are associated
with downregulation of AQP3.
AQP3 is a water channel predominantly expressed at the basolateral
plasma membrane of kidney collecting duct principal cells and is rarely
localized in the cytoplasmic vesicles (7). Expression levels of AQP3 were reduced after 24-h BUO and at 3 and 14 days after
release of BUO. The mechanisms underlying the regulation of AQP3
expression are presently not well understood. Previous studies have
shown that thirsting of normal rats for 48 h (7) or
dDAVP treatment of Brattleboro rats for 5 days (42)
induced a significant increase in AQP3 expression. Thus there is clear evidence that AQP3 regulation is linked to changes in vasopressin levels and water balance. Importantly, a significant role of AQP3 in
urinary concentration was recently demonstrated in AQP3 null mice that
manifest a dramatic polyuria and renal concentrating defect
(24). In addition, we have recently shown that AQP3
expression levels are dramatically reduced in response to 27 days of
lithium treatment, consistent with a significant polyuria and decreased urinary concentrating capacity. Moreover, we have shown that AQP3 is
also downregulated in other complex renal disease models such as
chronic renal failure induced by 5/6 nephrectomy (23), and ischemia-induced acute renal failure (22)
coinciding with a vasopressin-resistant polyuria and urinary
concentrating defect. Thus the reduced levels of AQP3 observed up to 14 days after release of BUO suggest that reduced AQP3 may also play a
significant role in the urinary concentrating defects after release of BUO.
BUO and release of BUO are associated with persisted downregulation
of AQP1.
We demonstrated that the expression of the proximal tubule and the
descending thin limb water channel AQP1 is significantly decreased in
response to 24-h BUO, and AQP1 expression levels remain decreased up to
30 days after release of BUO coinciding with the impaired urinary
concentrating capacity. BUO is characterized by a reduction in renal
blood flow, glomerular filtration rate (GFR), and oxygen tension in the
renal tissue (9, 13, 15). Thus the oxidative metabolism
necessary to generate ATP, especially in the proximale tubule, may be
very susceptible to hypoxic conditions. The reason for the consistent
reduction in AQP1 expression levels in whole kidney and inconsistent
reduction in the IM after release of obstruction remains to be
characterized. Recently, it was shown that AQP1 is required for the
formation of concentrated urine by the kidney, and decreased
transepithelial proximal tubule water permeability and defective fluid
absorption were found in AQP1 knockout mice, demonstrating that high
water permeability in the proximal tubules of wild-type mice is
primarily transcellular, is mediated by AQP1 water channels, and is
required for efficient near-isosmolar fluid absorption
(25).
Water transport in the thin descending limb of Henle's loop plays a
critical role in the countercurrent multiplier mechanism by assuring
osmotic equilibration between the descending limb lumen and the
surrounding interstitium (20). Studies of AQP1 knockout
mice have confirmed this concept by demonstrating that these mice have
a virtual absence of concentrating ability (25). Therefore, descreased abundance of AQP1 in the thin descending limb
would predict an impairment of urinary concentrating ability. The
finding of decreased AQP1 in the IM of BUO kidneys 2 wk after release,
reflecting a decrease in thin descending limb AQP1 abundance and a
presumed decrease in osmotic water permeability in the descending limb,
suggests that reduced AQP1 levels in the IM may participate in the
concentrating defect after release of BUO. In addition, it is highly
likely that a decrease in the driving force could result from transport
defects in the thick ascending limb long after obstruction is relieved,
contributing to the concentrating defect in the IM.
AQP1 abundance is also consistently decreased in the proximal tubule.
Because the proximal tubule plays no direct role in the urinary
concentrating mechanism, the significance of the decrease in AQP1 in
the proximal tubules is unclear. Isolated perfused tubule and
micropuncture studies in AQP1 knockout mice (38) have
demonstrated that the decrease in osmotic water permeability resulting
from AQP1 ablation leads to a decrease in NaCl reabsorption in the
proximal tubule. In the knockout mice, the decrease in proximal NaCl
reabsorption triggers a decrease in GFR, owing to the tubuloglomerular
feedback mechanism (37). A similar mechanism in BUO-R rats
may provide an explanation for decreased GFR in this model
(5). Decreased GFR may be expected to enhance urinary concentrating ability if all other factors were equal (1).
Thus AQP1 plays a key role for normal urinary-concentrating capacity.
The concomitant long-term reduction in urinary concentrating capacity
and AQP1 expression levels in the present study suggests that reduced
AQP1 may play a significant role in the urinary concentrating defect
after release of BUO.
Summary.
In conclusion, the expression of AQP1, AQP2, and AQP3 water channel
proteins was long-term downregulated after release of 24-h BUO,
suggesting that dysregulation of aquaporins located both at the
proximal tubule, the descending thin limb of Henle, and the collecting
duct may contribute to the long-term polyuria and impairment in urinary
concentrating capacity associated with obstructive nephropathy. The
observed downregulation of the collecting duct water channels AQP2 and
AQP3 may provide a molecular explanation for the functional defects
previously demonstrated in the collecting duct. It remains to be
established to what extent these defects contribute to polyuria.
Further studies are needed to examine whether BUO is associated with
alterations in the expression of sodium transporters that are
responsible for the establishment and maintenance of the hypertonic
medullary interstitium providing the driving force for water
reabsorption in the collecting duct.
 |
ACKNOWLEDGEMENTS |
The authors thank Gitte Christensen, Mette Vistisen, Helle Høyer,
Zhile Nikrozi, and Inger Merete Paulsen for expert technical assistance.
 |
FOOTNOTES |
Support for this study was provided by The Karen Elise Jensen
Foundation, The Novo Nordisk Foundation, The EU Commission (EU-TMR and
EU Biotech Programs), The Danish Medical Research Council, The
University of Aarhus Research Foundation, The Skovgaard Foundation, The
Danish Research Academy, and The University of Aarhus.
Address for reprint requests and other correspondence: J. Frøkiær, Institute of Experimental Clinical Research, Aarhus Univ. Hospital - Skejby, DK-8200 Aarhus, Denmark (E-mail:
JF{at}IEKF.AU.DK).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 28 December 2000; accepted in final form 8 March 2001.
 |
REFERENCES |
1.
Berliner, RW,
and
Bennett CM.
Concentration of urine in the mammalian kidney.
Am J Med
42:
777-789,
1967[ISI][Medline].
2.
Chou, CL,
Knepper MA,
Hoek AN,
Brown D,
Yang B,
Ma T,
and
Verkman AS.
Reduced water permeability and altered ultrastructure in thin descending limb of Henle in aquaporin-1 null mice.
J Clin Invest
103:
491-496,
1999[Abstract/Free Full Text].
3.
Chou, CL,
Ma T,
Yang B,
Knepper MA,
and
Verkman AS.
Fourfold reduction of water permeability in inner medullary collecting duct of aquaporin-4 knockout mice.
Am J Physiol Cell Physiol
274:
C549-C554,
1998[Abstract/Free Full Text].
4.
Curhan, GC,
and
Zeidel ML.
Urianry tract obstruction.
In: The Kidney, edited by Brenner BM,
and Rector FC.. Philadelphia, PA: Saunders, 1996, p. 1936-1958.
5.
Dal Canton, A,
Corradi A,
Stanziale R,
Maruccio G,
and
Migone L.
Glomerular hemodynamics before and after release of 24-h bilateral ureteral obstruction.
Kidney Int
17:
491-496,
1980[ISI][Medline].
6.
Earm, JH,
Christensen BM,
Frokiaer J,
Marples D,
Han JS,
Knepper MA,
and
Nielsen S.
Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats.
J Am Soc Nephrol
9:
2181-2193,
1998[Abstract].
7.
Ecelbarger, CA,
Terris J,
Frindt G,
Echevarria M,
Marples D,
Nielsen S,
and
Knepper MA.
Aquaporin-3 water channel localization and regulation in rat kidney.
Am J Physiol Renal Fluid Electrolyte Physiol
269:
F663-F672,
1995[Abstract/Free Full Text].
8.
Frokiaer, J,
Christensen BM,
Marples D,
Djurhuus JC,
Jensen UB,
Knepper MA,
and
Nielsen S.
Downregulation of aquaporin-2 parallels changes in renal water excretion in unilateral ureteral obstruction.
Am J Physiol Renal Physiol
273:
F213-F223,
1997[Abstract/Free Full Text].
9.
Frokiaer, J,
Knudsen L,
Nielsen AS,
Pedersen EB,
and
Djurhuus JC.
Enhanced intrarenal angiotensin II generation in response to obstruction of the pig ureter.
Am J Physiol Renal Fluid Electrolyte Physiol
263:
F527-F533,
1992[Abstract/Free Full Text].
10.
Frokiaer, J,
Marples D,
Knepper MA,
and
Nielsen S.
Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F657-F668,
1996[Abstract/Free Full Text].
11.
Garcia, NH,
Pomposiello SI,
and
Garvin JL.
Nitric oxide inhibits ADH-stimulated osmotic water permeability in cortical collecting ducts.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F206-F210,
1996[Abstract/Free Full Text].
12.
Garcia, NH,
Stoos BA,
Carretero OA,
and
Garvin JL.
Mechanism of the nitric oxide-induced blockade of collecting duct water permeability.
Hypertension
27:
679-683,
1996[Abstract/Free Full Text].
13.
Harris, RH,
and
Gill JM.
Changes in glomerular filtration rate during complete ureteral obstruction in rats.
Kidney Int
19:
603-608,
1981[ISI][Medline].
14.
Harris, RH,
and
Yarger WE.
The pathogenesis of postobstructive diuresis. The role of circulating natriuretic and diuretic factors, including urea .
J Clin Invest
56:
880-887,
1975[ISI][Medline].
15.
Heyman, SN,
Fuchs S,
Jaffe R,
Shina A,
Ellezian L,
Brezis M,
and
Rosen S.
Renal microcirculation and tissue damage during acute ureteral obstruction in the rat: effect of saline infusion, indomethacin and radiocontrast.
Kidney Int
51:
653-663,
1997[ISI][Medline].
16.
Ishibashi, K,
Sasaki S,
Fushimi K,
Uchida S,
Kuwahara M,
Saito H,
Furukawa T,
Nakajima K,
Yamaguchi Y,
Gojobori T,
and
Marumo F.
Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells.
Proc Natl Acad Sci USA
91:
6269-6273,
1994[Abstract].
17.
Klahr, S.
Pathophysiology of obstructive nephropathy. A 1991 update.
Semin Nephrol
11:
156-168,
1991[ISI][Medline].
18.
Knepper, MA.
Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin.
Am J Physiol Renal Physiol
272:
F3-F12,
1997[Abstract/Free Full Text].
19.
Knepper, MA,
Nielsen S,
Chou CL,
and
DiGiovanni SR.
Mechanism of vasopressin action in the renal collecting duct.
Semin Nephrol
14:
302-321,
1994[ISI][Medline].
20.
Knepper, MA,
and
Rector FC, Jr.
Urinary concentration and dilution.
In: The Kidney, edited by Brenner BM,
and Rector FC.. Philadelphia, PA: Saunders, 1996, vol. I, p. 532-570.
21.
Knepper, MA,
Verbalis JG,
and
Nielsen S.
Role of aquaporins in water balance disorders.
Curr Opin Nephrol Hypertens
6:
367-371,
1997[ISI][Medline].
22.
Kwon, TH,
Frokiaer J,
Fernandez-Llama P,
Knepper MA,
and
Nielsen S.
Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: prevention by alpha-MSH.
Am J Physiol Renal Physiol
277:
F413-F427,
1999[Abstract/Free Full Text].
23.
Kwon, TH,
Frokiaer J,
Knepper MA,
and
Nielsen S.
Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass.
Am J Physiol Renal Physiol
275:
F724-F741,
1998[Abstract/Free Full Text].
24.
Ma, T,
Song Y,
Yang B,
Gillespie A,
Carlson EJ,
Epstein CJ,
and
Verkman AS.
Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels.
Proc Natl Acad Sci USA
97:
4386-4391,
2000[Abstract/Free Full Text].
25.
Ma, T,
Yang B,
Gillespie A,
Carlson EJ,
Epstein CJ,
and
Verkman AS.
Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels.
J Biol Chem
273:
4296-4299,
1998[Abstract/Free Full Text].
26.
Marples, D,
Christensen S,
Christensen EI,
Ottosen PD,
and
Nielsen S.
Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.
J Clin Invest
95:
1838-1845,
1995[ISI][Medline].
27.
Marples, D,
Frokiaer J,
Dorup J,
Knepper MA,
and
Nielsen S.
Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex.
J Clin Invest
97:
1960-1968,
1996[Abstract/Free Full Text].
28.
Marples, D,
Frokiaer J,
and
Nielsen S.
Long-term regulation of aquaporins in the kidney.
Am J Physiol Renal Physiol
276:
F331-F339,
1999[Abstract/Free Full Text].
29.
Marples, D,
Knepper MA,
Christensen EI,
and
Nielsen S.
Redistribution of aquaporin-2 water channels induced by vasopressin in rat kidney inner medullary collecting duct.
Am J Physiol Cell Physiol
269:
C655-C664,
1995[Abstract].
30.
Nielsen, S,
Chou CL,
Marples D,
Christensen EI,
Kishore BK,
and
Knepper MA.
Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane.
Proc Natl Acad Sci USA
92:
1013-1017,
1995[Abstract].
31.
Nielsen, S,
DiGiovanni SR,
Christensen EI,
Knepper MA,
and
Harris HW.
Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney.
Proc Natl Acad Sci USA
90:
11663-11667,
1993[Abstract].
32.
Nielsen, S,
Kwon TH,
Christensen BM,
Promeneur D,
Frokiaer J,
and
Marples D.
Physiology and pathophysiology of renal aquaporins.
J Am Soc Nephrol
10:
647-663,
1999[Abstract/Free Full Text].
33.
Nielsen, S,
Smith B,
Christensen EI,
Knepper MA,
and
Agre P.
CHIP28 water channels are localized in constitutively water-permeable segments of the nephron.
J Cell Biol
120:
371-383,
1993[Abstract].
34.
Sands, JM,
Flores FX,
Kato A,
Baum MA,
Brown EM,
Ward DT,
Hebert SC,
and
Harris HW.
Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats.
Am J Physiol Renal Physiol
274:
F978-F985,
1998[Abstract/Free Full Text].
35.
Sands, JM,
Naruse M,
Jacobs JD,
Wilcox JN,
and
Klein JD.
Changes in aquaporin-2 protein contribute to the urine concentrating defect in rats fed a low-protein diet.
J Clin Invest
97:
2807-2814,
1996[Abstract/Free Full Text].
36.
Sasaki, S,
Fushimi K,
Saito H,
Saito F,
Uchida S,
Ishibashi K,
Kuwahara M,
Ikeuchi T,
Inui K,
Nakajima K,
and
a. et.
Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct.
J Clin Invest
93:
1250-1256,
1994[ISI][Medline].
37.
Schnermann, J.
NaCl transport deficiencies-hemodynamics to the rescue.
Pflügers Arch
439:
682-690,
2000[ISI][Medline].
38.
Schnermann, J,
Chou CL,
Ma T,
Traynor T,
Knepper MA,
and
Verkman AS.
Defective proximal tubular fluid reabsorption in transgenic aquaporin-1 null mice.
Proc Natl Acad Sci USA
95:
9660-9664,
1998[Abstract/Free Full Text].
39.
Sonnenberg, H,
and
Wilson DR.
The role of the medullary collecting ducts in postobstructive diuresis.
J Clin Invest
57:
1564-1574,
1976[ISI][Medline].
40.
Stoos, BA,
Garcia NH,
and
Garvin JL.
Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct.
J Am Soc Nephrol
6:
89-94,
1995[Abstract].
41.
Swenson, KL,
Sands JM,
Jacobs JD,
and
Sladek CD.
Effect of aging on vasopressin and aquaporin responses to dehydration in Fischer 344-brown-Norway F1 rats.
Am J Physiol Regulatory Integrative Comp Physiol
273:
R35-R40,
1997[Abstract/Free Full Text].
42.
Terris, J,
Ecelbarger CA,
Nielsen S,
and
Knepper MA.
Long-term regulation of four renal aquaporins in rats.
Am J Physiol Renal Fluid Electrolyte Physiol
271:
F414-F422,
1996[Abstract/Free Full Text].
43.
Yarger, WE,
Aynedjian HS,
and
Bank N.
A micropuncture study of postobstructive diuresis in the rat.
J Clin Invest
51:
625-637,
1972[ISI][Medline].
Am J Physiol Renal Fluid Electrolyte Physiol 281(1):F163-F171
0363-6127/01 $5.00
Copyright © 2001 the American Physiological Society